Cargando…
Natalizumab treatment reduces L-selectin (CD62L) in CD4(+) T cells
BACKGROUND: The purpose of this research was to validate the low expression of L-selectin (CD62L) in natalizumab (NTZ)-treated patients. CD62L is involved in rolling and transmigration of leukocyte cells. A correlation between CD62LCD4(+) T cells low expression and progressive multifocal leukoenceph...
Autores principales: | Spadaro, Michela, Caldano, Marzia, Marnetto, Fabiana, Lugaresi, Alessandra, Bertolotto, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532246/ https://www.ncbi.nlm.nih.gov/pubmed/26259673 http://dx.doi.org/10.1186/s12974-015-0365-x |
Ejemplares similares
-
Suppression of Foxo1 Activity and Down-Modulation of CD62L (L-Selectin) in HIV-1 Infected Resting CD4 T Cells
por: Trinité, Benjamin, et al.
Publicado: (2014) -
L-Selectin/CD62L Is a Key Driver of Non-Alcoholic Steatohepatitis in Mice and Men
por: Drescher, Hannah K., et al.
Publicado: (2020) -
The Shedding of CD62L (L-Selectin) Regulates the Acquisition of Lytic Activity in Human Tumor Reactive T Lymphocytes
por: Yang, Shicheng, et al.
Publicado: (2011) -
CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients
por: Lieberman, Linda A., et al.
Publicado: (2016) -
Structural requirements regulate endoproteolytic release of the L- selectin (CD62L) adhesion receptor from the cell surface of leukocytes
Publicado: (1995)